Explore research of chemoimmunotherapy and angiogenesis inhibitor for KRAS-mutant non-small cell lung cancer patients; prospective observation study
Not Applicable
Recruiting
- Conditions
- on-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000049780
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients deemed inappropriate by the physician in charge.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival: PFS
- Secondary Outcome Measures
Name Time Method Time to treatment failure: TTF Overall survival: OS Overall response rate; ORR Disease control rate; DCR Adverse events including immune related adverse events.